DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for amelogenesis imperfecta type 3B — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAmelogenesis imperfecta type 3B maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for amelogenesis imperfecta type 3b is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The three abstracts provided are all supplemental materials for a single 2023 paper on novel ameloblastin variants and contrasting amelogenesis imperfecta phenotypes. They contain no data on any drug, treatment, or intervention. The paper identifies new genetic variants in the AMBN gene that cause different forms of amelogenesis imperfecta, but no therapeutic agent is tested, no survival or response rates are reported, and no sample sizes for any treatment group are given. There is no mention of drug repurposing or any pharmacological approach.
Because the abstracts describe only genetic findings and phenotypic contrasts, there is no evidence to support any drug for amelogenesis imperfecta type 3B. The paper does not address whether existing drugs might modify the condition. No clinical trial results, no animal model drug data, and no in vitro drug screens are presented.
What is missing for this disease is any published research testing a drug in patients or in preclinical models. There are no trials, no repurposing candidates, and no stratified patient populations that have been treated. The genetic basis is being clarified, but therapeutic development remains at the stage of basic discovery, with no funding or trial design yet directed at a pharmacological intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Sage Journals Data · 2023 · 0 citations · open access
sj-docx-1-jdr-10.1177_00220345231203694 – Supplemental material for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes
AbstractSupplemental material, sj-docx-1-jdr-10.1177_00220345231203694 for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes by U. Hany, C.M. Watson, L. Liu, G. Nikolopoulos, C.E.L. Smith, J.A. Poulter, C.J. Brown, A. Patel, H.D. Rodd, R. Balmer, A. Harfoush, M. Al-Jawad, C.F. Inglehearn and A.J. Mighell in Journal of Dental Research
INDIGO (University of Illinois at Chicago) · 2023 · 0 citations · open access
sj-pptx-1-jdr-10.1177_00220345231203694 – Supplemental material for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes
AbstractSupplemental material, sj-pptx-1-jdr-10.1177_00220345231203694 for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes by U. Hany, C.M. Watson, L. Liu, G. Nikolopoulos, C.E.L. Smith, J.A. Poulter, C.J. Brown, A. Patel, H.D. Rodd, R. Balmer, A. Harfoush, M. Al-Jawad, C.F. Inglehearn and A.J. Mighell in Journal of Dental Research
Sage Journals Data · 2023 · 0 citations · open access
sj-pptx-1-jdr-10.1177_00220345231203694 – Supplemental material for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes
AbstractSupplemental material, sj-pptx-1-jdr-10.1177_00220345231203694 for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes by U. Hany, C.M. Watson, L. Liu, G. Nikolopoulos, C.E.L. Smith, J.A. Poulter, C.J. Brown, A. Patel, H.D. Rodd, R. Balmer, A. Harfoush, M. Al-Jawad, C.F. Inglehearn and A.J. Mighell in Journal of Dental Research
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
